Press releases
- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
As of last trade Organon & Co (7XP:BER) traded at 19.26, -12.16% below its 52-week high of 21.92, set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.27 |
---|---|
High | 19.27 |
Low | 19.26 |
Bid | 18.99 |
Offer | 19.58 |
Previous close | 19.32 |
Average volume | 352.44 |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.15 |
Market cap | 5.40bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.04 EUR |
---|---|
Annual div yield (ADY) | 5.38% |
Div ex-date | May 10 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 15 minutes, as of May 29 2024 09:10 BST.
More ▼